While the MUC1-based mRNA vaccine elicited an antigen-specific cytotoxic T-cell response and enhanced T-cell infiltration into the tumor, the combination with CTLA-4 siRNA appeared to enhance this effect. The gene discussed is CTLA4; the disease is neoplasm.